Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study.
Gabay C., Bel M., Combescure C., Ribi C., Meier S., Posfay-Barbe K., Grillet S., Seebach J.D., Kaiser L., Wunderli W. et al., 2011/06. Arthritis and rheumatism, 63 (6) pp. 1486-1496. Peer-reviewed.
ici le détail